Alterola Biotech, Inc. Logo

Alterola Biotech, Inc.

ABTI

(1.8)
Stock Price

0,00 USD

-426.95% ROA

-20.2% ROE

-8.55x PER

Market Cap.

26.271.036,00 USD

-76.69% DER

0% Yield

0% NPM

Alterola Biotech, Inc. Stock Analysis

Alterola Biotech, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Alterola Biotech, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.54x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

4 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

5 ROE

The stock's ROE indicates a negative return (-13.98%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-626.55%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Alterola Biotech, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Alterola Biotech, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Sell
4 Stoch RSI Hold

Alterola Biotech, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Alterola Biotech, Inc. Revenue
Year Revenue Growth
2010 0
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Alterola Biotech, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2010 0
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 2.432.210 100%
2023 46.422 -5139.35%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Alterola Biotech, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2010 78.634
2011 124.915 37.05%
2012 97.695 -27.86%
2013 3.650 -2576.58%
2014 59.132 93.83%
2015 40.915 -44.52%
2016 20.402 -100.54%
2017 11.631 -75.41%
2018 46.549 75.01%
2019 122.557 62.02%
2020 258.453 52.58%
2021 329.511 21.56%
2022 4.038.925 91.84%
2023 1.650.559 -144.7%
2024 492.628 -235.05%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Alterola Biotech, Inc. EBITDA
Year EBITDA Growth
2010 -96.903
2011 -126.781 23.57%
2012 -97.695 -29.77%
2013 -3.650 -2576.58%
2014 -62.007 94.11%
2015 -40.915 -51.55%
2016 -19.885 -105.76%
2017 -11.631 -70.97%
2018 -46.549 75.01%
2019 -122.557 62.02%
2020 -258.453 52.58%
2021 -250.511 -3.17%
2022 -6.471.135 96.13%
2023 -1.696.981 -281.33%
2024 -492.628 -244.48%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Alterola Biotech, Inc. Gross Profit
Year Gross Profit Growth
2010 0
2011 -1.866 100%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Alterola Biotech, Inc. Net Profit
Year Net Profit Growth
2010 -97.238
2011 -128.871 24.55%
2012 -106.112 -21.45%
2013 -13.250 -700.85%
2014 -72.501 81.72%
2015 -54.915 -32.02%
2016 -36.127 -52.01%
2017 -22.577 -60.02%
2018 -86.132 73.79%
2019 -133.067 35.27%
2020 -258.702 48.56%
2021 -171.511 -50.84%
2022 -6.471.134 97.35%
2023 -1.542.457 -319.53%
2024 -492.620 -213.11%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Alterola Biotech, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2010 0
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Alterola Biotech, Inc. Free Cashflow
Year Free Cashflow Growth
2010 -99.225
2011 -137.195 27.68%
2012 -61.986 -121.33%
2013 0 0%
2014 -30.673 100%
2015 -16.077 -90.79%
2016 -17.369 7.44%
2017 -27.631 37.14%
2018 0 0%
2019 -19.950 100%
2020 0 0%
2021 0 0%
2022 44.344 100%
2023 -1.179.591 103.76%
2024 -122.158 -865.63%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Alterola Biotech, Inc. Operating Cashflow
Year Operating Cashflow Growth
2010 -99.225
2011 -125.995 21.25%
2012 -61.986 -103.26%
2013 0 0%
2014 -30.673 100%
2015 -16.077 -90.79%
2016 -17.369 7.44%
2017 -27.631 37.14%
2018 0 0%
2019 -19.950 100%
2020 0 0%
2021 0 0%
2022 44.344 100%
2023 -1.039.792 104.26%
2024 -122.158 -751.19%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Alterola Biotech, Inc. Capital Expenditure
Year Capital Expenditure Growth
2010 0
2011 11.200 100%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 139.799 100%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Alterola Biotech, Inc. Equity
Year Equity Growth
2010 4.849
2011 -57.522 108.43%
2012 -101.676 43.43%
2013 -114.926 11.53%
2014 -150.427 23.6%
2015 -205.342 26.74%
2016 -241.469 14.96%
2017 -264.046 8.55%
2018 -294.678 10.4%
2019 -55.567 -430.31%
2020 -202.710 72.59%
2021 -323.221 37.28%
2022 10.926.276 102.96%
2023 10.095.547 -8.23%
2024 -2.022.023 599.28%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Alterola Biotech, Inc. Assets
Year Assets Growth
2010 7.224
2011 28.228 74.41%
2012 6.200 -355.29%
2013 6.200 0%
2014 29.152 78.73%
2015 6.200 -370.19%
2016 8.314 25.43%
2017 2.583 -221.87%
2018 0 0%
2019 50.742 100%
2020 14.742 -244.2%
2021 15.273 3.48%
2022 12.127.961 99.87%
2023 12.376.963 2.01%
2024 497.208 -2389.29%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Alterola Biotech, Inc. Liabilities
Year Liabilities Growth
2010 2.375
2011 85.750 97.23%
2012 107.876 20.51%
2013 121.126 10.94%
2014 179.579 32.55%
2015 211.542 15.11%
2016 249.783 15.31%
2017 266.629 6.32%
2018 294.678 9.52%
2019 106.309 -177.19%
2020 217.452 51.11%
2021 338.494 35.76%
2022 1.201.685 71.83%
2023 2.281.416 47.33%
2024 2.519.231 9.44%

Alterola Biotech, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-8.55x
Price To Sales Ratio
0x
POCF Ratio
-36.44
PFCF Ratio
-121.33
Price to Book Ratio
-3.56
EV to Sales
0
EV Over EBITDA
-39.52
EV to Operating CashFlow
-140.73
EV to FreeCashFlow
-128.45
Earnings Yield
-0.12
FreeCashFlow Yield
-0.01
Market Cap
0,03 Bil.
Enterprise Value
0,03 Bil.
Graham Number
0.01
Graham NetNet
-0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.23
ROE
-0.2
Return On Assets
-1.69
Return On Capital Employed
0.35
Net Income per EBT
1
EBT Per Ebit
1.2
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
-0.1
Capex to Revenue
0
Capex to Depreciation
4.4
Return on Invested Capital
1.49
Return on Tangible Assets
-4.27
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
-0
Shareholders Equity per Share
-0
Interest Debt per Share
0
Debt to Equity
-0.77
Debt to Assets
3.12
Net Debt to EBITDA
-2.19
Current Ratio
0.08
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-2022023
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.6
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
992
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Alterola Biotech, Inc. Dividends
Year Dividends Growth

Alterola Biotech, Inc. Profile

About Alterola Biotech, Inc.

Alterola Biotech, Inc., a pharmaceutical company, engages in the development of cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products; production of active pharmaceutical ingredients and food-grade ingredients; and formulation and drug delivery for improved bioavailability, solubility, and stability. The company is based in Birkenhead, the United Kingdom.

CEO
Mr. David John Hitchcock O.B.E
Employee
0
Address
47 Hamilton Square
Birkenhead, CH41 5AR

Alterola Biotech, Inc. Executives & BODs

Alterola Biotech, Inc. Executives & BODs
# Name Age
1 Mr. Timothy Paul Rogers
Executive Chairman
70
2 Mr. David John Hitchcock O.B.E.
Chief Executive Officer & Director
70
3 Mr. Nathan Thompson
Chief Financial Officer, Secretary & Director
70
4 Mr. Colin G. Stott B.Sc.
Chief Operating Officer & Director
70
5 Mr. Dominic Schiller
IP Counsel, Chief IP Officer & Director
70

Alterola Biotech, Inc. Competitors